California Department of Justice

Dinant Expands Investment in Local Communities

Retrieved on:

Tuesday, November 29, 2022

TEGUCIGALPA, HONDURAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Dinant increased its investment in local communities throughout Honduras in 2022, providing a range of support from repairing schools and donating food and cleaning supplies to providing human rights training and planting trees.

Key Points:

TEGUCIGALPA, HONDURAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Dinant increased its investment in local communities throughout Honduras in 2022, providing a range of support from repairing schools and donating food and cleaning supplies to providing human rights training and planting trees.
Roger Pineda Pinel, Dinants Director of Corporate Relations and Sustainability, said, Dinant has invested extensively in health and nutrition, education, infrastructure, education, environmental sustainability and philanthropy for local communities in 2022, benefitting nearly 44,000 people in Honduras.
Local infrastructure problems continue to hamper many communities.In Comayagua, Dinant donated materials for the construction of a bridge to make life easier for 120 local families.
The partnerships we have formed with local people have improved the living standards of thousands of Hondurans, and were excited to do more next year.

FDA and FTC Dietary Supplements Promotion and Advertising Compliance Regulations Webinar

Retrieved on:

Wednesday, November 2, 2022

California Department of Justice, Justice, Dietary supplement, Advertising, Compliance, FTC, FTC regulation of behavioral advertising, Department, FDA, Consent, Pharmaceutical industry

DUBLIN, Nov. 2, 2022 /PRNewswire/ --The "Promoting and Advertising Dietary Supplements in Compliance with FDA and FTC Regulations" webinar has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Nov. 2, 2022 /PRNewswire/ --The "Promoting and Advertising Dietary Supplements in Compliance with FDA and FTC Regulations" webinar has been added to ResearchAndMarkets.com's offering.
This 2-hr webinar will review the FDA and FTC regulations for promoting and advertising dietary supplements, walk you through real-life case studies, help you address compliance, and provide practical advice on how to respond to an enforcement action.
FDA and FTC routinely initiate enforcement actions, including Untitled Letters, Warning Letters, Recalls, etc., against dietary supplement makers who misbrand their products by violating FDA advertising and promotion regulations, e.g., by claiming the product can treat, cure, prevent, mitigate or diagnose disease.
Is your organization in compliance with FDA advertising and promotion regulations?

EHR provider Modernizing Medicine pays $45M to settle DOJ, whistleblower case alleging False Claims Act Violations, Kickbacks

Retrieved on:

Tuesday, November 1, 2022

The alleged illegal conduct included providing Miraca with exclusive "enhanced" laboratory interfaces within ModMed's EHR that would drive diagnostic testing business to Miraca.

Key Points:

The alleged illegal conduct included providing Miraca with exclusive "enhanced" laboratory interfaces within ModMed's EHR that would drive diagnostic testing business to Miraca.
It is also significant because it resolves allegations concerning illegal referral arrangements between the EHR vendor and a clinical laboratory, Miraca.
This is believed to be the first time the United States has taken enforcement action under the False Claims Act against an EHR vendor for providing preferential treatment for a clinical laboratory.
The "relator," or whistleblower, in the False Claims Act case isAmanda (Mandy) Long.

FDA and FTC Dietary Supplements Promotion and Advertising Compliance Regulations Webinar - ResearchAndMarkets.com

Retrieved on:

Friday, October 21, 2022

Fitness & Nutrition, Health, Advertising, Justice, Compliance, California Department of Justice, Consent, Department, FDA, Review, Dietary supplement, FTC, Pharmaceutical industry

This 2-hr webinar will review the FDA and FTC regulations for promoting and advertising dietary supplements, walk you through real-life case studies, help you address compliance, and provide practical advice on how to respond to an enforcement action.

Key Points:

This 2-hr webinar will review the FDA and FTC regulations for promoting and advertising dietary supplements, walk you through real-life case studies, help you address compliance, and provide practical advice on how to respond to an enforcement action.
FDA and FTC routinely initiate enforcement actions, including Untitled Letters, Warning Letters, Recalls, etc., against dietary supplement makers who misbrand their products by violating FDA advertising and promotion regulations, e.g., by claiming the product can treat, cure, prevent, mitigate or diagnose disease.
Is your organization in compliance with FDA advertising and promotion regulations?
This webinar will review the applicable regulations, walk you through real-life situations, help you address compliance, and provide practical strategies to mitigate enforcement actions.

Socure Estimates Financial Losses from Synthetic Fraud to Reach Nearly $5B by 2024

Retrieved on:

Thursday, October 20, 2022

If synthetic identity fraud continues to go unchecked, losses will double from the estimated $2.48 billion this year to nearly $5 billion in 2024, the research shows.

Key Points:

If synthetic identity fraud continues to go unchecked, losses will double from the estimated $2.48 billion this year to nearly $5 billion in 2024, the research shows.
The report documents some of the most recent patterns employed by synthetic fraudsters, such as launching increased attacks on demand deposit accounts (DDAs).
At Socure, we strongly believe we can eradicate synthetic fraud within the next three years, and stop the damage that bad actors are committing against consumers and our financial system.
Synthetic Identity Fraud is Growing, Morphing
The Department of Justice has said that synthetic identity fraud is the countrys fastest growing financial crime.

Socure Launches Newest Sigma Synthetic Fraud Model Adding Unrivaled Precision to its Identity Fraud Suite

Retrieved on:

Thursday, October 20, 2022

Socure , the leading provider of digital identity verification and fraud solutions, today announced the debut of its newest Sigma Synthetic Fraud model, a synthetic identity fraud detection solution that identifies manipulated and fabricated identities with unmatched precision.

Key Points:

Socure , the leading provider of digital identity verification and fraud solutions, today announced the debut of its newest Sigma Synthetic Fraud model, a synthetic identity fraud detection solution that identifies manipulated and fabricated identities with unmatched precision.
Core to the precision of Sigma Synthetic Fraud is the integration of two critical fraud-fighting features: powerful machine learning technology (ML) and expert fraud investigators.
Socure combines the knowledge and expertise of fraud investigators with the computational and statistical capabilities of advanced ML, making its solution highly effective in detecting synthetic identity fraud.
With Sigma Synthetic Fraud, Socure fraud investigators provide clean, corrected, and properly classified fraud labels for unlabeled or mislabeled raw data.

FDA, DOJ Seek Permanent Injunctions Against Six E-cigarette Manufacturers

Retrieved on:

Tuesday, October 18, 2022

SILVER SPRING, Md., Oct. 18, 2022 /PRNewswire/ -- Today, the U.S. Department of Justice (DOJ), on behalf of the U.S. Food and Drug Administration, filed complaints for permanent injunctions in federal district courts against six e-cigarette manufacturers. These cases represent the first time the FDA has initiated injunction proceedings to enforce the Federal Food, Drug, and Cosmetic (FD&C) Act's premarket review requirements for new tobacco products.

Key Points:

SILVER SPRING, Md., Oct. 18, 2022 /PRNewswire/ -- Today, the U.S. Department of Justice (DOJ), on behalf of the U.S. Food and Drug Administration, filed complaints for permanent injunctions in federal district courts against six e-cigarette manufacturers.
The injunctions would require the companies and named individuals to stop manufacturing, selling, and distributing their e-cigarettes.
The injunctions would also require the defendants to obtain marketing authorization from the FDA before marketing such products, as required by law.
"We will not stand by as manufacturers repeatedly break the law, especially after being afforded multiple opportunities to comply."

Revitalist Non-Profit, “Community Change Foundation”, Receives $1M Grant to Address Adolescent Mental Health and School Violence

Retrieved on:

Monday, October 3, 2022

The federal grant, Preventing School Violence: Bureau of Justice Assistances STOP School Violence Program, will be used in conjunction with Revitalists proprietary REAP the Zone athletic program along with nationally recognized programs from Stand4Kind and Navigate360 directly addressing the mental health of adolescents.

Key Points:

The federal grant, Preventing School Violence: Bureau of Justice Assistances STOP School Violence Program, will be used in conjunction with Revitalists proprietary REAP the Zone athletic program along with nationally recognized programs from Stand4Kind and Navigate360 directly addressing the mental health of adolescents.
Revitalist CEO, Kathryn Walker, states I created Revitalist and Community Change Foundation to work in conjunction with for-profit and non-profit partners to bring positive change to our current environment.
Community Change Foundation is a national nonprofit 501c3 focusing on providing financing and resources to community members seeking to improve their mental health and wellness.
To learn more about Community Change Foundation, please watch the video below, Community Change Foundation .

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Retrieved on:

Monday, September 19, 2022

Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, AIM ImmunoTech, SIGN, Patient, AND, National Diet of Japan Fukushima Nuclear Accident Independent Investigation Commission, CARD, Leadership, Drug development, California Department of Justice, Food, DATE, THE, Annual general meeting, Vanderbilt University School of Medicine, Company, Liver, Accounting, CKM, DNA, SEC, INTERNET, AIM, NYSE, Ovarian cancer, Association, Cancer, THOMAS, Bring Your Board!!, Board, Pathology, Fatigue, Department, Justice, Erasmus MC, Colorectal cancer, Pancreatic cancer, American Association, OR, Activism, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast cancer, BOARD, Board of directors, Holding company, Pharmaceutical industry, Medical device, Online gambling, Medical imaging, Management, Rintatolimod, Shareholder, American

The Board of Directors (Board) of AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), today announced that the Company has filed its Definitive Proxy Statement in connection with AIMs upcoming 2022 Annual Meeting of Stockholders (the Annual Meeting), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.

Key Points:

The Board of Directors (Board) of AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), today announced that the Company has filed its Definitive Proxy Statement in connection with AIMs upcoming 2022 Annual Meeting of Stockholders (the Annual Meeting), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.
Thank you for your investment and your trust in AIM ImmunoTech (AIM or the Company).
The Board has unanimously determined that Mr. Jorgls director nominations did not comply with AIMs bylaws and are invalid.
THE BOARD RECOMMENDS A VOTE FOR ALL OF OUR BOARDS NOMINEES (STEWART L. APPELROUTH, THOMAS K. EQUELS AND WILLIAM M. MITCHELL)ON PROPOSAL 1 USING THE ENCLOSED WHITE PROXY CARD.

ASSA ABLOY statement on the U.S. Department of Justice´s opposition to the acquisition of the Hardware and Home Improvement ("HHI") division of Spectrum Brands

Retrieved on:

Thursday, September 15, 2022

ASSA ABLOY and Spectrum Brands strongly disagree with the Department of Justice's characterization of the proposed transaction, and will vigorously contest in court this effort by the DOJ to oppose the transaction.

Key Points:

ASSA ABLOY and Spectrum Brands strongly disagree with the Department of Justice's characterization of the proposed transaction, and will vigorously contest in court this effort by the DOJ to oppose the transaction.
ASSA ABLOY and Spectrum Brands remain confident in the merits of this transaction and will jointly defend it.
ASSA ABLOY and Spectrum Brands are committed to completing the transaction and are confident that they will prevail in litigation.
As previously disclosed, ASSA ABLOY and Spectrum Brands have agreed to extend their agreement for ASSA ABLOY to acquire HHI to June 30, 2023.